相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia
Pierre Blais et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Practice patterns in NAFLD and NASH: real life differs from published guidelines
Mary E. Rinella et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans
Fasiha Kanwal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
Scott Friedman et al.
CONTEMPORARY CLINICAL TRIALS (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Alexandra Montagner et al.
GUT (2016)
NDI-010976, A POTENT, LIVER-DIRECTED, ORAL INHIBITOR OF ACETYL COA CARBOXYLASE FOR NON-ALCOHOLIC STEATOHEPATITIS: PHARMACODYNAMIC EFFECTS ON HEPATIC DE NOVO LIPOGENESIS IN OBESE BUT OTHERWISE HEALTHY ADULT MALE VOLUNTEERS
W. F. Westlin et al.
JOURNAL OF HEPATOLOGY (2016)
SITAGLIPTIN VERSUS PLACEBO IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED CONTROLLED TRIAL
J. Y. Cui et al.
JOURNAL OF HEPATOLOGY (2016)
Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis
Mei Xiang et al.
JOURNAL OF HEPATOLOGY (2016)
REDUCTION OF LIVER STEATOSIS AND FIBROSIS WITH AN ASK1 INHIBITOR IN A MURINE MODEL OF NASH IS ACCOMPANIED BY IMPROVEMENTS IN CHOLESTEROL, BILE ACID AND LIPID METABOLISM
G. Budas et al.
JOURNAL OF HEPATOLOGY (2016)
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Matthew J. Armstrong et al.
JOURNAL OF HEPATOLOGY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
Hiroyuki Kato et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease
Daniele Pastori et al.
DIGESTIVE AND LIVER DISEASE (2015)
Challenges and Opportunities in Drug and Biomarker Development for Nonalcoholic Steatohepatitis: Findings and Recommendations From an American Association for the Study of Liver Diseases-US Food and Drug Administration Joint Workshop
Arun J. Sanyal et al.
HEPATOLOGY (2015)
Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)
Rohit Loomba et al.
HEPATOLOGY (2015)
Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up
Mattias Ekstedt et al.
HEPATOLOGY (2015)
TREATMENT WITH NGM282 SIGNIFICANTLY IMPROVES LIVER HISTOPATHOLOGY IN A MOUSE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
J. Luo et al.
JOURNAL OF HEPATOLOGY (2015)
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
Michaela Mueller et al.
JOURNAL OF HEPATOLOGY (2015)
Statin use and non-alcoholic steatohepatitis in at risk individuals
Paola Dongiovanni et al.
JOURNAL OF HEPATOLOGY (2015)
A PLACEBO-CONTROLLED, MULTICENTER, DOUBLE-BLIND, RANDOMISED TRIAL OF EMRICASAN IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND RAISED TRANSAMINASES
M. Shiffman et al.
JOURNAL OF HEPATOLOGY (2015)
PHASE 1 RESULTS FROM PXS-4728A, A SELECTIVE SSAO/VAP-1 INHIBITOR, FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
W. Jarolimek et al.
JOURNAL OF HEPATOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Prednisolone or Pentoxifylline for Alcoholic Hepatitis
Mark R. Thursz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications
Vi Nguyen et al.
SEMINARS IN LIVER DISEASE (2015)
miRNA-103: Molecular link between insulin resistance and nonalcoholic fatty liver disease
Qian Xu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome
Konstantinos Kargiotis et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Vascular adhesion protein-1 promotes liver inflammation and drives hepatic
Chris J. Weston et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
Fernando J. Barreyro et al.
LIVER INTERNATIONAL (2015)
Sulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation
Shunlin Ren et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
Peroxisome Proliferator-Activated Receptor δ Agonist GW1516 Attenuates Diet-Induced Aortic Inflammation, Insulin Resistance, and Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice
Lazar A. Bojic et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
The Fatty Acid-Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
Rifaat Safadi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Knocking on FXR's Door: The Hammerhead-Structure Series of FXR Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities
Christian Gege et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2014)
The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects
Remy Hanf et al.
DIABETES & VASCULAR DISEASE RESEARCH (2014)
A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
Rajendrakumar H. Jani et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2014)
850f Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model
Prabhavathi Fernandes et al.
GASTROENTEROLOGY (2014)
Roles for Chemokines in Liver Disease
Fabio Marra et al.
GASTROENTEROLOGY (2014)
Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
Jennifer E. Lambert et al.
GASTROENTEROLOGY (2014)
Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation A Randomized Clinical Trial
Takara L. Stanley et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis
Juan Du et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
M. J. Armstrong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player
Lazar A. Bojic et al.
CURRENT OPINION IN LIPIDOLOGY (2013)
Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
Bertrand Cariou et al.
DIABETES CARE (2013)
Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Bart Staels et al.
HEPATOLOGY (2013)
Prednisolone With vs Without Pentoxifylline and Survival of Patients With Severe Alcoholic Hepatitis A Randomized Clinical Trial
Philippe Mathurin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease
Rachel H. McMahan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related metabolic dysfunctions in mice
Shannon M. Reilly et al.
NATURE MEDICINE (2013)
Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)-Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins
Jerry R. Colca et al.
PLOS ONE (2013)
Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
Peter G. Traber et al.
PLOS ONE (2013)
Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes
Lihong Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
Liver cholesterol: is it playing possum in NASH?
Geoffrey C. Farrell et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells
T. Adar et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2012)
FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents
James Mu et al.
DIABETES (2012)
Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy
Hitoshi Nishizawa et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome
Anne Vrieze et al.
GASTROENTEROLOGY (2012)
Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography
Vincent Wai-Sun Wong et al.
GUT (2012)
Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial
Thuy-Anh Le et al.
HEPATOLOGY (2012)
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism
Claudia O. Zein et al.
HEPATOLOGY (2012)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
Insulin Resistance and Metabolic Derangements in Obese Mice Are Ameliorated by a Novel Peroxisome Proliferator-activated Receptor γ-sparing Thiazolidinedione
Zhouji Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Malonyl-CoA: the regulator of fatty acid synthesis and oxidation
Daniel W. Foster
JOURNAL OF CLINICAL INVESTIGATION (2012)
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
Geoffrey Porez et al.
JOURNAL OF LIPID RESEARCH (2012)
PPARs: Fatty acid sensors controlling metabolism
Lars la Cour Poulsen et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2012)
Treatment of NASH with ursodeoxycholic acid: Cons
Fabia Liechti et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2012)
Treatment of NASH with ursodeoxycholic acid: Pro
Vlad Ratziu
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2012)
The role of chemokines in acute liver injury
Yedidya Saiman et al.
FRONTIERS IN PHYSIOLOGY (2012)
Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease
R. Dohil et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
Christopher D. Williams et al.
GASTROENTEROLOGY (2011)
Pentoxifylline Improves Nonalcoholic Steatohepatitis: A Randomized Placebo-Controlled Trial
Claudia O. Zein et al.
HEPATOLOGY (2011)
Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Eric A. Klein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
MicroRNAs 103 and 107 regulate insulin sensitivity
Mirko Trajkovski et al.
NATURE (2011)
Fatty Acid Bile Acid Conjugate Inhibits Hepatic Stearoyl Coenzyme A Desaturase and Is Non-atherogenic
Alicia Leikin-Frenkel et al.
ARCHIVES OF MEDICAL RESEARCH (2010)
Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
Elisa Fabbrini et al.
HEPATOLOGY (2010)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
Bile Salt Sequestration Induces Hepatic De Novo Lipogenesis Through Farnesoid X Receptor- and Liver X Receptorα-Controlled Metabolic Pathways in Mice
Hilde Herrema et al.
HEPATOLOGY (2010)
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
Giovanni Musso et al.
HEPATOLOGY (2010)
Hepatic Lipotoxicity and the Pathogenesis of Nonalcoholic Steatohepatitis: the Central Role of Nontriglyceride Fatty Acid Metabolites
Brent A. Neuschwander-Tetri
HEPATOLOGY (2010)
FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation
Xinle Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment
Vivian Barry-Hamilton et al.
NATURE MEDICINE (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Hepatic Expression Patterns of Inflammatory and Immune Response Genes Associated with Obesity and NASH in Morbidly Obese Patients
Adeline Bertola et al.
PLOS ONE (2010)
Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials
Markus Schuerks et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
The Protein Kinase IKKε Regulates Energy Balance in Obese Mice
Shian-Huey Chiang et al.
CELL (2009)
Apoptosis and Cytokinesin Non-Alcoholic Steatohepatitis
Wing-Kin Syn et al.
CLINICS IN LIVER DISEASE (2009)
Reduction of Hepatic Steatosis in Rats and Mice After Treatment with a Liver-Targeted Thyroid Hormone Receptor Agonist
Edward E. Cable et al.
HEPATOLOGY (2009)
Orlistat for Overweight Subjects with Nonalcoholic Steatohepatitis: A Randomized, Prospective Trial
Stephen A. Harrison et al.
HEPATOLOGY (2009)
The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
Rania Abu-Hamdah et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease
Elisa Fabbrini et al.
GASTROENTEROLOGY (2008)
Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatly acid oxidation in moderately obese men
Ulf Riserus et al.
DIABETES (2008)
A lipidomic analysis of nonalcoholic fatty liver disease
Puneet Puri et al.
HEPATOLOGY (2007)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C
Paul J. Pockros et al.
HEPATOLOGY (2007)
Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets
Jonathan D. Brown et al.
CIRCULATION (2007)
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
John B. Buse et al.
CLINICAL THERAPEUTICS (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
Shira Zelber-Sagi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
First-in-class pan caspase inhibitor developed for the treatment of liver disease
SD Linton et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Apoptosis in alcoholic and nonalcoholic steatohepatitis
AE Feldstein et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality
ER Miller et al.
ANNALS OF INTERNAL MEDICINE (2005)
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
JD Browning et al.
HEPATOLOGY (2004)
A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis
K Promrat et al.
HEPATOLOGY (2004)
Vitamin E and transfer proteins
DE Kaempf-Rotzoll et al.
CURRENT OPINION IN LIPIDOLOGY (2003)
Bile acid binding to sevelamer HCl
W Braunlin et al.
KIDNEY INTERNATIONAL (2002)
Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells
PF Lalor et al.
JOURNAL OF IMMUNOLOGY (2002)
Medical progress - Nonalcoholic fatty liver disease
P Angulo
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
AJ Sanyal et al.
GASTROENTEROLOGY (2001)
Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial
E Akriviadis et al.
GASTROENTEROLOGY (2000)
分享论文
